NUAK family SNF1-like kinase 2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NUAK family SNF1-like kinase 2 as ChEMBL target CHEMBL5698, mapped to UniProt Q9H093. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why NUAK family SNF1-like kinase 2 matters
NUAK family SNF1-like kinase 2 is reviewed as NUAK family SNF1-like kinase 2 (UniProt Q9H093); the current evidence base includes 12 approved drugs, 563 compounds, and 196 assays, with lead potency reaching pChEMBL 10.1.
NUAK family SNF1-like kinase 2 Sequence length is 628 aa.
Review this target as NUAK family SNF1-like kinase 2, mapped to UniProt Q9H093. Sequence length is 628 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 12 approved drugs, 563 compounds, and 196 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why NUAK family SNF1-like kinase 2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H093, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
10.1 | Kd | — |
|
|
No preferred name
CHEMBL3904602
|
9.2 | Kd | Clinical |
|
|
No preferred name
CHEMBL603469
|
9.0 | Kd | Clinical |
|
|
No preferred name
CHEMBL509032
|
8.9 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
8.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
TOFACITINIB CITRATE
CHEMBL2103743
|
2012 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |